PL373806A1 - Nowe fizjologicznie czynne substancje - Google Patents
Nowe fizjologicznie czynne substancjeInfo
- Publication number
- PL373806A1 PL373806A1 PL03373806A PL37380603A PL373806A1 PL 373806 A1 PL373806 A1 PL 373806A1 PL 03373806 A PL03373806 A PL 03373806A PL 37380603 A PL37380603 A PL 37380603A PL 373806 A1 PL373806 A1 PL 373806A1
- Authority
- PL
- Poland
- Prior art keywords
- physiolgically
- novel
- active substances
- substances
- active
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002155853 | 2002-05-29 | ||
JP2002223355 | 2002-07-31 | ||
JP2003063176 | 2003-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL373806A1 true PL373806A1 (pl) | 2005-09-19 |
Family
ID=29587471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03373806A PL373806A1 (pl) | 2002-05-29 | 2003-05-29 | Nowe fizjologicznie czynne substancje |
Country Status (17)
Country | Link |
---|---|
US (4) | US20060009439A1 (pl) |
EP (3) | EP2927228B1 (pl) |
JP (2) | JP4491341B2 (pl) |
KR (1) | KR100954401B1 (pl) |
CN (2) | CN1665807B (pl) |
AU (1) | AU2003241927C1 (pl) |
BR (1) | BR0311331A (pl) |
CA (1) | CA2486728C (pl) |
ES (1) | ES2603803T3 (pl) |
IL (2) | IL165388A0 (pl) |
IS (1) | IS7571A (pl) |
MX (1) | MXPA04011885A (pl) |
NO (1) | NO20045679L (pl) |
NZ (1) | NZ536778A (pl) |
PL (1) | PL373806A1 (pl) |
TW (1) | TWI334866B (pl) |
WO (1) | WO2003099813A1 (pl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI311558B (en) | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
WO2004011459A1 (ja) | 2002-07-31 | 2004-02-05 | Mercian Corporation | 新規生理活性物質 |
CA2507641A1 (en) | 2002-11-29 | 2004-06-17 | Mercian Corporation | Method of producing macrolide compound |
US7932083B2 (en) | 2003-11-27 | 2011-04-26 | Mercian Corporation | DNA participating in hydroxylation of macrolide compound |
US7655442B2 (en) * | 2004-01-29 | 2010-02-02 | Eisai R&D Management Co., Ltd. | Method for stabilizing macrolide compounds |
WO2005075681A1 (ja) * | 2004-02-06 | 2005-08-18 | Eisai R & D Management Co., Ltd. | 抗癌剤に対する癌細胞の感受性を検定する方法 |
CA2574092C (en) | 2004-07-20 | 2011-08-23 | Eisai R & D Management Co., Ltd. | Dna coding for polypeptide participating in biosynthesis of pladienolide |
JPWO2007043621A1 (ja) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドb及びプラジエノライドdの全合成方法 |
JPWO2008016187A1 (ja) * | 2006-08-02 | 2009-12-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライド類のターゲット分子、本ターゲット分子に結合する化合物、及びそのスクリーニング方法 |
CA2659562A1 (en) * | 2006-08-14 | 2008-02-21 | Eisai R&D Management Co., Ltd. | Stable lyophilized preparation |
PE20081705A1 (es) * | 2007-01-29 | 2008-12-22 | Eisai Randd Man Co Ltd | Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene |
EP2136209A4 (en) | 2007-03-05 | 2010-10-27 | Eisai R&D Man Co Ltd | METHOD FOR EXAMINING AN ACTION OF AN ANTI-CANCER AGENT USING A SPLICE DEFECT AS A MEASUREMENT |
WO2008111466A1 (ja) | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | 遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法 |
US20080312317A1 (en) * | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
US20100197919A1 (en) * | 2007-07-06 | 2010-08-05 | Toshio Tsuchida | Method for producing macrolide compound and production intermediate thereof |
GB0821539D0 (en) * | 2008-11-25 | 2008-12-31 | Merlion Pharmaceuticals Pte Ltd | Therapeutic compounds and their use |
EP3514154B1 (en) | 2014-05-15 | 2022-08-03 | Eisai R&D Management Co., Ltd. | Pladienolide pyridine compounds and methods of use |
EP3344780B1 (en) | 2015-09-01 | 2021-06-23 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
IL259198B2 (en) | 2015-11-18 | 2023-04-01 | Eisai R&D Man Co Ltd | A solid form of paladinolide pyridine compound and methods of its use |
JP2020514348A (ja) | 2017-03-15 | 2020-05-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スプライセオソーム変異及びその使用 |
PE20212327A1 (es) | 2018-04-09 | 2021-12-14 | Eisai Randd Man Co Ltd | Ciertos compuestos de pladienolida y metodos de uso |
CN117285502A (zh) | 2018-04-12 | 2023-12-26 | 卫材R&D管理有限公司 | 作为用于治疗癌症的剪接体靶向剂的普拉二烯内酯衍生物 |
IL305047A (en) | 2018-06-01 | 2023-10-01 | Eisai R&D Man Co Ltd | Methods for using splicing modulators |
EP3801632A1 (en) * | 2018-06-01 | 2021-04-14 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
RU195959U1 (ru) * | 2019-09-23 | 2020-02-11 | Анна Александровна Золотенкова | Устройство для механической нейростимуляции языка |
EP4161966A1 (en) | 2020-06-05 | 2023-04-12 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
WO2022098712A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL27183A (en) | 1966-02-01 | 1970-07-19 | Upjohn Co | Parenteral composition comprising freeze dried mannitol |
JPS6054933B2 (ja) | 1978-01-27 | 1985-12-03 | 小野薬品工業株式会社 | プロスタグランジン及びプロスタグランジン類似化合物製剤の安定化法 |
JPH04352783A (ja) * | 1991-05-27 | 1992-12-07 | Taisho Pharmaceut Co Ltd | 12員環マクロライド系化合物 |
HUT75780A (en) | 1994-04-25 | 1997-05-28 | Kyowa Hakko Kogyo Kk | Method for stabilizing compound dx-52-1 (isoquinolino-pyrolo-pyrazine derivatives) and lyophilized composition thereof |
WO2000075126A1 (en) * | 1999-06-03 | 2000-12-14 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Mycolactone and related compounds, compositions and methods of use |
US6391903B1 (en) | 1999-09-09 | 2002-05-21 | Sankyo Company, Limited | Triazole derivatives having antifungal activity |
JP3240129B1 (ja) | 1999-09-09 | 2001-12-17 | 三共株式会社 | トリアゾール抗真菌剤 |
JP4953501B2 (ja) | 1999-09-30 | 2012-06-13 | 大塚化学株式会社 | 3−セフェム誘導体結晶の製造方法 |
US6562602B2 (en) | 2000-08-03 | 2003-05-13 | Kosan Biosciences, Inc. | Fermentation and purification of mycolactones |
TWI311558B (en) * | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
TWI233361B (en) * | 2001-04-13 | 2005-06-01 | Gen Hospital Corp | Methods of preventing UVB-induced skin damage |
TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
JP2004269488A (ja) | 2002-06-06 | 2004-09-30 | Hayashibara Biochem Lab Inc | 結晶α−D−グルコシルα−D−ガラクトシドとこれを含有する糖質及びこれらの製造方法並びに用途 |
WO2004011459A1 (ja) | 2002-07-31 | 2004-02-05 | Mercian Corporation | 新規生理活性物質 |
KR101285695B1 (ko) * | 2002-07-31 | 2013-07-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규한 생리 활성 물질 |
CA2507641A1 (en) | 2002-11-29 | 2004-06-17 | Mercian Corporation | Method of producing macrolide compound |
US20050106275A1 (en) | 2003-05-02 | 2005-05-19 | Chen Su | Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells |
ATE493134T1 (de) | 2003-05-07 | 2011-01-15 | Eisai R&D Man Co Ltd | Gefriergetrocknetes präparat mit methylcobalamin und verfahren zu seiner herstellung |
US7655442B2 (en) | 2004-01-29 | 2010-02-02 | Eisai R&D Management Co., Ltd. | Method for stabilizing macrolide compounds |
JP2007269628A (ja) | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
JPWO2006075690A1 (ja) | 2005-01-14 | 2008-06-12 | 小野薬品工業株式会社 | 安定な医薬組成物 |
CA2607639A1 (en) | 2005-05-11 | 2006-11-16 | Eisai R & D Management Co., Ltd. | Crystal of indole derivative having piperidine ring and process for production thereof |
JPWO2007043621A1 (ja) * | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドb及びプラジエノライドdの全合成方法 |
CA2659562A1 (en) | 2006-08-14 | 2008-02-21 | Eisai R&D Management Co., Ltd. | Stable lyophilized preparation |
PE20081705A1 (es) * | 2007-01-29 | 2008-12-22 | Eisai Randd Man Co Ltd | Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene |
-
2003
- 2003-05-28 TW TW092114449A patent/TWI334866B/zh not_active IP Right Cessation
- 2003-05-29 EP EP15157945.5A patent/EP2927228B1/en not_active Expired - Lifetime
- 2003-05-29 EP EP03733172A patent/EP1508570A4/en not_active Withdrawn
- 2003-05-29 CN CN038155966A patent/CN1665807B/zh not_active Expired - Fee Related
- 2003-05-29 BR BR0311331-0A patent/BR0311331A/pt not_active Application Discontinuation
- 2003-05-29 PL PL03373806A patent/PL373806A1/pl not_active Application Discontinuation
- 2003-05-29 KR KR1020047019406A patent/KR100954401B1/ko not_active IP Right Cessation
- 2003-05-29 US US10/515,647 patent/US20060009439A1/en not_active Abandoned
- 2003-05-29 CA CA2486728A patent/CA2486728C/en not_active Expired - Fee Related
- 2003-05-29 CN CN038155966A patent/CN1665807A/zh active Granted
- 2003-05-29 MX MXPA04011885A patent/MXPA04011885A/es active IP Right Grant
- 2003-05-29 JP JP2004507470A patent/JP4491341B2/ja not_active Expired - Lifetime
- 2003-05-29 AU AU2003241927A patent/AU2003241927C1/en not_active Ceased
- 2003-05-29 ES ES15157945.5T patent/ES2603803T3/es not_active Expired - Lifetime
- 2003-05-29 WO PCT/JP2003/006779 patent/WO2003099813A1/ja active Application Filing
- 2003-05-29 EP EP20100178687 patent/EP2266978B1/en not_active Expired - Lifetime
- 2003-05-29 NZ NZ536778A patent/NZ536778A/en not_active IP Right Cessation
- 2003-05-29 IL IL16538803A patent/IL165388A0/xx unknown
-
2004
- 2004-11-24 IL IL165388A patent/IL165388A/en not_active IP Right Cessation
- 2004-11-29 IS IS7571A patent/IS7571A/is unknown
- 2004-12-28 NO NO20045679A patent/NO20045679L/no not_active Application Discontinuation
-
2006
- 2006-06-23 US US11/473,201 patent/US7550503B2/en active Active
-
2007
- 2007-10-29 US US11/927,564 patent/US7893068B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,542 patent/US7619100B2/en not_active Expired - Fee Related
-
2010
- 2010-02-26 JP JP2010041261A patent/JP2010132693A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL373806A1 (pl) | Nowe fizjologicznie czynne substancje | |
AU2003249738A8 (en) | Ostoscope | |
AU2003297193A8 (en) | Meta-web | |
EP1548121A4 (en) | NEW PHYSIOLOGICALLY ACTIVE SUBSTANCES | |
AU2003252028A8 (en) | Heterodiamondoids | |
AU2003279495A8 (en) | Alert-modeling | |
DE50303619D1 (en) | Reibschweissvorrichtung | |
DE50307787D1 (en) | Isophthalsäurederivate | |
GB0221745D0 (en) | Active martrix display | |
AU2003264900A8 (en) | Cast-cutter | |
AU2002367810A8 (en) | Bis-transition-metal-chelate-probes | |
DE50304964D1 (en) | Handhobelmaschine | |
GB0201520D0 (en) | Pharmaceutical uses | |
AU2003262681A8 (en) | Hemo-aide | |
DE10392833D2 (en) | Geotextilie | |
AU2003253735A8 (en) | Vacuolins | |
AU2002341221A8 (en) | Honey-brandy | |
GB0215011D0 (en) | Easy squeezy | |
GB0219146D0 (en) | Substances | |
CA94979S (en) | Disinfectant center | |
AU2326P (en) | Gavol Gazania rigens | |
AU2329P (en) | Gaula Gaura lindheimeri | |
CA94955S (en) | Handleset | |
AU3429P (en) | Ohakea Hebe diosmifolia | |
AU3399P (en) | Kosciuszko xTriticosecale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |